Inventor · disambiguated record
Karen Silence
Also filed as: SILENCE KAREN
22 granted patents·31 pending applications·246 citations·filing 1999–2025
95Inventor score
Top patents by PatentIndex Score
53 records- 0197US7807162B2Single domain VHH antibodies against von Willebrand factorABLYNX NV·Filed 2006·Granted Oct 5, 2010·72 cites·6 claims
- 0294US9765149B2Antibodies to CD70ARGEN-X N V·Filed 2014·Granted Sep 19, 2017·24 cites·22 claims
- 0394US9765148B2Antibodies to CD70SILENCE KAREN·Filed 2012·Granted Sep 19, 2017·32 cites·13 claims
- 0494US8834882B2Antibodies to CD70SILENCE KAREN·Filed 2013·Granted Sep 16, 2014·30 cites·12 claims
- 0591US8097251B2Functional heavy chain antibodies, fragments thereof, library thereof and methods of production thereofMUYLDERMANS SERGE·Filed 2006·Granted Jan 17, 2012·22 cites·2 claims
- 0690US12344678B2FcRn/HSA binding molecules and methods of useargenx BV·Filed 2024·Granted Jul 1, 2025·3 cites·14 claims
- 0790US8372398B2Single domain VHH antibodies against Von Willebrand FactorABLYNX NV·Filed 2010·Granted Feb 12, 2013·14 cites·12 claims
- 0887US9371381B2Single domain antibodies directed against tumor necrosis factor-alpha and uses thereforABLYNX NV·Filed 2014·Granted Jun 21, 2016·5 cites·16 claims
- 0985US9926364B2Chimeric human-llama antigens and methods of useARGEN X N V·Filed 2012·Granted Mar 27, 2018·5 cites·18 claims
- 1083US11434298B2Antibodies to CD70argenx BV·Filed 2019·Granted Sep 6, 2022·1 cites·11 claims
- 1183US11072665B2Antibodies to CD70ARGENX BVBA·Filed 2015·Granted Jul 27, 2021·2 cites·39 claims
- 1283US9320792B2Pulmonary administration of immunoglobulin single variable domains and constructs thereofABLYNX NV·Filed 2013·Granted Apr 26, 2016·4 cites·6 claims
- 1381US9725522B2Pulmonary administration of immunoglobulin single variable domains and constructs thereofABLYNX NV·Filed 2016·Granted Aug 8, 2017·2 cites·7 claims
- 1481US2023265201A1Antibodies to cd70argenx BV·Filed 2022·Application pending·0 cites
- 1579US7939277B2Methods and assays for distinguishing between different forms of diseases and disorders characterized by thrombocytopenia and/or by spontaneous interaction between Von Willebrand Factor (vWF) and plateletsUMC UTRECHT HOLDING BV·Filed 2006·Granted May 10, 2011·12 cites·24 claims
- 1677US10391168B1Anti-CD70 combination therapyUNIV OF BERN·Filed 2015·Granted Aug 27, 2019·4 cites·21 claims
- 1776US11571475B1Anti-CD70 and BCR-ABL inhibitor combination therapyUNIV OF BERN·Filed 2019·Granted Feb 7, 2023·1 cites·10 claims
- 1875US9243065B2Polypeptide constructs including VHH directed against EGFR for intracellular deliverySILENCE KAREN·Filed 2009·Granted Jan 26, 2016·2 cites·3 claims
- 1971US2025382388A1Fcrn/hsa binding molecules and methods of useargenx BV·Filed 2025·Application pending·0 cites
- 2070US2025122288A1Fcrn binding molecules and methods of useargenx BV·Filed 2024·Application pending·0 cites
- 2168US9028816B2Polypeptides and polypeptide constructs comprising single domain antibodies directed against von Willebrand factorSILENCE KAREN·Filed 2004·Granted May 12, 2015·3 cites·27 claims
- 2266US11492401B2Therapeutic musk antibodiesUNIV NEW YORK·Filed 2021·Granted Nov 8, 2022·0 cites·24 claims
- 2366US11034755B2Polypeptides and polypeptide constructs comprising single domain antibodies directed against von willebrand factorABLYNX NV·Filed 2018·Granted Jun 15, 2021·0 cites·4 claims
- 2464US2009022721A1Single domain antibodies directed against tumour necrosis factor-alpha and uses thereforABLYNX NV·Filed 2007·Application pending·0 cites
- 2564US2007237769A1Single domain antibodies directed against tumour necrosis factor-alpha and uses thereforABLYNX NV·Filed 2007·Application pending·0 cites
- 2663US2015064182A1Stabilized single domain antibodiesABLYNX NV·Filed 2014·Application pending·0 cites
- 2763US2007077249A1Single domain antibodies directed against tumour necrosis factor-alpha and uses thereforABLYNX NV·Filed 2006·Application pending·0 cites
- 2863US2010003253A1Single domain antibodies directed against epidermal growth factor receptor and uses thereforABLYNX NV·Filed 2009·Application pending·0 cites
- 2962US2009238829A1Stabilized single domain antibodiesABLYNX NV·Filed 2007·Application pending·0 cites
- 3062US2011158996A1Von willebrand factor specific binders and methods of use thereforABLYNX NV·Filed 2009·Application pending·0 cites
- 3162US2017096481A1Single domain antibodies directed against tumor necrosis factor-alpha and uses thereforABLYNX NV·Filed 2016·Application pending·0 cites
- 3260US2012202977A1Single domain antibodies directed against tumor necrosis factor-alpha and uses thereforSILENCE KAREN·Filed 2012·Application pending·0 cites
- 3360US2025051477A1Anti-musk antibodies for use in treating neuromuscular disordersargenx BV·Filed 2024·Application pending·0 cites
- 3459US2011184150A1Single domain antibodies directed against tumor necrosis factor-alpha and uses thereforABLYNX NV·Filed 2011·Application pending·0 cites
- 3559US2025188190A1In utero treatment of a fetus having genetic disease/neuromuscular diseaseargenx BV·Filed 2024·Application pending·0 cites
- 3658US2011027281A1Single domain antibodies directed against tumor necrosis factor-alpha and uses thereforABLYNX NV·Filed 2010·Application pending·0 cites
- 3757US2006034845A1Single domain antibodies directed against tumor necrosis factor alpha and uses thereforSILENCE KAREN·Filed 2003·Application pending·0 cites
- 3857US2017107302A1Stabilized single domain antibodiesABLYNX NV·Filed 2016·Application pending·0 cites
- 3957US2012251540A1Stabilized single domain antibodiesSILENCE KAREN·Filed 2012·Application pending·0 cites
- 4056US2011178277A1Stabilized single domain antibodiesABLYNX NV·Filed 2011·Application pending·0 cites
- 4156US2023151091A1Therapeutic musk antibodiesARGENX IIP BV·Filed 2022·Application pending·0 cites
- 4253US2013136736A1Single Domain VHH Antibodies Against Von Willebrand FactorSILENCE KAREN·Filed 2013·Application pending·0 cites
- 4352US2011184151A1Single domain antibodies directed against epidermal growth factor receptor and uses thereforABLYNX NV·Filed 2011·Application pending·0 cites
- 4452US2011123529A1Single domain antibodies directed against epidermal growth factor receptor and uses thereforABLYNX NV·Filed 2011·Application pending·0 cites
- 4551US10112989B2Polypeptides and polypeptide constructs comprising single domain antibodies directed against von Willebrand factorABLYNX NV·Filed 2015·Granted Oct 30, 2018·0 cites·8 claims
- 4651US6479280B1Recombinant phages capable of entering host cells via specific interaction with an artificial receptorVLAAMS INTERUNIV INST BIOTECH·Filed 1999·Granted Nov 12, 2002·8 cites·10 claims
- 4751US2006115470A1Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disordersABLYNX NV·Filed 2003·Application pending·0 cites
- 4851US2003148508A1Recombinant phages capable of entering host cells via specific interaction with an artificial receptorVLAAMS INTERUNIV INST BIOTECH·Filed 2002·Application pending·0 cites
- 4949US2014044710A1Von willebrand factor specific binders and methods of use thereforABLYNX NV·Filed 2013·Application pending·0 cites
- 5048US2011184145A1Method of administering therapeutic polypeptides, and polypeptides thereforABLYNX NV·Filed 2011·Application pending·0 cites
Showing the top 50 of 53 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Karen Silence files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →